Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
04 March 1994Website:
http://www.biocryst.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 23:26:00 GMTDividend
Analysts recommendations
Institutional Ownership
BCRX Latest News
The company announced its first-quarter earnings that morning, achieving strong results in both revenue and profit.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) held its Q1 2024 Earnings Call on May 6, 2024 at 8:30 AM ET. Company representatives included John Bluth, Jon Stonehouse, Charlie Gayer, Helen Thackray, and Anthony Doyle. Various analysts from firms such as Jefferies, Bank of America, and Evercore ISI also participated in the call. The operator welcomed all participants to the call and reminded them that it would be in listen-only mode.
BioCryst Pharmaceuticals (BCRX) reported a quarterly loss of $0.17 per share, beating the Zacks Consensus Estimate of a loss of $0.23. This is an improvement from the loss of $0.28 per share reported in the same quarter last year.
BioCryst (BCRX) has the ideal mix of factors that could lead to better-than-expected earnings in its upcoming report. Make sure you are ready with the main expectations.
RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024, at 2:30 p.m. ET and the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15 a.m. ET.
Each of these hidden penny stock gems have the potential to provide triple digit growth to investors. Investors are forever on the lookout for Investments that can turn $1 into $2 or more.
BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.38 per share a year ago.
RESEARCH TRIANGLE PARK, N.C. , Feb. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts featuring new analyses of real-world use of oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting. The meeting will take place at the Walter E. Washington Convention Center in Washington, D.C., from February 23-26, 2024.
BioCryst (BCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
BioCryst Pharmaceuticals, Inc. proof-of-concept data from a phase 1 study, using BCX10013 for the treatment of patients with complement-mediated disorders, is expected in 2024. Oral C2, C5, and Bifunctional inhibitor drugs are also being advanced to treat patients with complement-mediated disorders. Net revenue for Q3 of 2023 came in at $85.7 million, which was a 29.8% year-over-year increase.
What type of business is BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
What sector is BioCryst Pharmaceuticals in?
BioCryst Pharmaceuticals is in the Healthcare sector
What industry is BioCryst Pharmaceuticals in?
BioCryst Pharmaceuticals is in the Biotechnology industry
What country is BioCryst Pharmaceuticals from?
BioCryst Pharmaceuticals is headquartered in United States
When did BioCryst Pharmaceuticals go public?
BioCryst Pharmaceuticals initial public offering (IPO) was on 04 March 1994
What is BioCryst Pharmaceuticals website?
https://www.biocryst.com
Is BioCryst Pharmaceuticals in the S&P 500?
No, BioCryst Pharmaceuticals is not included in the S&P 500 index
Is BioCryst Pharmaceuticals in the NASDAQ 100?
No, BioCryst Pharmaceuticals is not included in the NASDAQ 100 index
Is BioCryst Pharmaceuticals in the Dow Jones?
No, BioCryst Pharmaceuticals is not included in the Dow Jones index
When does BioCryst Pharmaceuticals report earnings?
The next expected earnings date for BioCryst Pharmaceuticals is 02 August 2024